CY1106697T1 - Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων - Google Patents

Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων

Info

Publication number
CY1106697T1
CY1106697T1 CY20071100881T CY071100881T CY1106697T1 CY 1106697 T1 CY1106697 T1 CY 1106697T1 CY 20071100881 T CY20071100881 T CY 20071100881T CY 071100881 T CY071100881 T CY 071100881T CY 1106697 T1 CY1106697 T1 CY 1106697T1
Authority
CY
Cyprus
Prior art keywords
formula
hydromorphones
substituted
substituted hydromorphones
compounds
Prior art date
Application number
CY20071100881T
Other languages
English (en)
Inventor
Donald J. Kyle
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1106697T1 publication Critical patent/CY1106697T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αυτή αφορά Ν-υποκατεστημένες υδρομορφόνες του Τύπου Ι ή φαρμακευτικώς αποδεκτό άλας αυτών. Αυτές οι ενώσεις δρουν ως αγωνιστές υποδοχέα μ οπιοειδούς. Η εφεύρεση επίσης κατευθύνεται στη χρήση ενώσεων του Τύπου Ι για την θεραπεία, πρόληψη ή ανακούφιση τόσο οξέος όσο και χρόνιου πόνου.
CY20071100881T 2002-09-25 2007-07-03 Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων CY1106697T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41325402P 2002-09-25 2002-09-25
PCT/US2003/029876 WO2004029059A1 (en) 2002-09-25 2003-09-24 N-substituted hydromorphones and the use thereof

Publications (1)

Publication Number Publication Date
CY1106697T1 true CY1106697T1 (el) 2012-05-23

Family

ID=32043224

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100881T CY1106697T1 (el) 2002-09-25 2007-07-03 Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων

Country Status (19)

Country Link
US (1) US6825205B2 (el)
EP (2) EP1543010B1 (el)
JP (2) JP4806190B2 (el)
KR (1) KR20050074462A (el)
CN (1) CN100387600C (el)
AT (1) ATE360633T1 (el)
AU (1) AU2003272642B2 (el)
BR (1) BR0314488A (el)
CA (1) CA2500118C (el)
CY (1) CY1106697T1 (el)
DE (1) DE60313478T2 (el)
DK (1) DK1543010T3 (el)
ES (1) ES2286461T3 (el)
HK (1) HK1080456A1 (el)
MX (1) MXPA05003104A (el)
NZ (1) NZ538726A (el)
PT (1) PT1543010E (el)
WO (1) WO2004029059A1 (el)
ZA (1) ZA200502174B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
NZ575620A (en) 2006-09-20 2010-11-26 Mallinckrodt Inc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
JP2010510326A (ja) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド ４，５−エポキシ−モルフィナニウム類似体のｎ−オキシド類
CA2670382A1 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
EP2137189B1 (en) 2007-03-06 2015-05-06 Mallinckrodt LLC Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
CA2694497C (en) * 2007-08-09 2016-07-12 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009070733A1 (en) * 2007-11-26 2009-06-04 Pharmacofore, Inc. Peripheral phenolic opioid antagonist
JP6027315B2 (ja) 2008-05-27 2016-11-16 マリンクロッド エルエルシー ノルモルフィナンの調製のための方法および化合物
WO2010028004A2 (en) 2008-09-03 2010-03-11 Mallinckrodt Inc. Substituted berbines and processes for their synthesis
WO2012038813A1 (en) 2010-09-21 2012-03-29 Purdue Pharma L.P. Buprenorphine analogs
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
US9056836B2 (en) 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
US9988392B2 (en) 2013-12-26 2018-06-05 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
CA2934913A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
JP2017521373A (ja) 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ATE78687T1 (de) * 1987-09-10 1992-08-15 Univ Chicago Quaternaere derivate von noroxymorphon zur behandlung von uebelkeit und erbrechen.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP1310251A1 (en) * 1996-11-25 2003-05-14 Toray Industries, Inc. Antipruritic agent
WO2001014382A1 (fr) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesiques contenant des derives sel d'ammonium quaternaire comme principe actif

Also Published As

Publication number Publication date
AU2003272642B2 (en) 2009-07-09
DE60313478D1 (de) 2007-06-06
CN100387600C (zh) 2008-05-14
CN1684967A (zh) 2005-10-19
ATE360633T1 (de) 2007-05-15
ZA200502174B (en) 2006-05-31
DE60313478T2 (de) 2008-01-03
HK1080456A1 (en) 2006-04-28
JP2011042681A (ja) 2011-03-03
ES2286461T3 (es) 2007-12-01
PT1543010E (pt) 2007-07-26
MXPA05003104A (es) 2005-05-27
US6825205B2 (en) 2004-11-30
NZ538726A (en) 2006-11-30
EP1543010A1 (en) 2005-06-22
BR0314488A (pt) 2005-08-02
EP1803724A1 (en) 2007-07-04
DK1543010T3 (da) 2007-09-17
CA2500118C (en) 2011-04-12
EP1543010B1 (en) 2007-04-25
AU2003272642A1 (en) 2004-04-19
KR20050074462A (ko) 2005-07-18
JP4806190B2 (ja) 2011-11-02
JP2006503850A (ja) 2006-02-02
US20040067973A1 (en) 2004-04-08
WO2004029059A1 (en) 2004-04-08
CA2500118A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
ATE440603T1 (de) 8-hydroxychinolinderivate
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
SE9902267D0 (sv) New compounds
HK1057886A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
GEP201606538B (en) Preoperative treatment of post operative pain
BR0206687A (pt) Método para prevenir e tratar dores viscerais e distúrbios gastrointestinais
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
NO20033634L (no) GLyT-1-inhibitorer
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы
CY1110207T1 (el) Φαρμακευτικοι συνδυασμοι υδροκοδωνης και ναλτρεξονης